In Vitro-In Vivo Extrapolation of Intestinal Availability for Carboxylesterase Substrates Using Portal Vein-Cannulated Monkey.
暂无分享,去创建一个
T. Maurer | D. Scott | K. Beaumont | L. Di | Patrick E. Trapa | H. Eng | Karen Atkinson | Amanda J King-Ahmad | Amanda J. King-Ahmad
[1] S. Bhadresa,et al. Pharmacokinetics of IDX184, a liver-targeted oral prodrug of 2′-methylguanosine-5′-monophosphate, in the monkey and formulation optimization for human exposure , 2016, European Journal of Drug Metabolism and Pharmacokinetics.
[2] S. Mandlekar,et al. Absorption and cleavage of enalapril, a carboxyl ester prodrug, in the rat intestine: in vitro, in situ intestinal perfusion and portal vein cannulation models , 2015, Biopharmaceutics & drug disposition.
[3] Kayoko Ohura,et al. Design of Fexofenadine Prodrugs Based on Tissue-Specific Esterase Activity and Their Dissimilar Recognition by P-Glycoprotein. , 2015, Journal of pharmaceutical sciences.
[4] S. Yamashita,et al. Quantitative Assessment of Intestinal First-pass Metabolism of Oral Drugs Using Portal-vein Cannulated Rats , 2015, Pharmaceutical Research.
[5] Aleksandra Galetin,et al. Hepatic, Intestinal, Renal, and Plasma Hydrolysis of Prodrugs in Human, Cynomolgus Monkey, Dog, and Rat: Implications for In Vitro–In Vivo Extrapolation of Clearance of Prodrugs , 2014, Drug Metabolism and Disposition.
[6] Hugues Dolgos,et al. Utility of In Vitro Systems and Preclinical Data for the Prediction of Human Intestinal First-Pass Metabolism during Drug Discovery and Preclinical Development , 2013, Drug Metabolism and Disposition.
[7] S. Yamashita,et al. In Vivo Assessment of the Impact of Efflux Transporter on Oral Drug Absorption Using Portal Vein–Cannulated Rats , 2013, Drug Metabolism and Disposition.
[8] X. Chu,et al. Species differences in drug transporters and implications for translating preclinical findings to humans , 2013, Expert opinion on drug metabolism & toxicology.
[9] William A. Lee,et al. Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. , 2013, Molecular pharmaceutics.
[10] V. Herring,et al. The Role of Human Carboxylesterases in Drug Metabolism: Have We Overlooked Their Importance? , 2013, Pharmacotherapy.
[11] S. Yamashita,et al. Assessment of Intestinal Availability of Various Drugs in the Oral Absorption Process Using Portal Vein-Cannulated Rats , 2012, Drug Metabolism and Disposition.
[12] Yuichiro Sato,et al. Simultaneous Absolute Protein Quantification of Carboxylesterases 1 and 2 in Human Liver Tissue Fractions using Liquid Chromatography-Tandem Mass Spectrometry , 2012, Drug Metabolism and Disposition.
[13] Kevin C. Johnson. Comparison of methods for predicting dissolution and the theoretical implications of particle-size-dependent solubility. , 2012, Journal of pharmaceutical sciences.
[14] E. T. Williams,et al. Characterization of the Expression and Activity of Carboxylesterases 1 and 2 from the Beagle Dog, Cynomolgus Monkey, and Human , 2011, Drug Metabolism and Disposition.
[15] Li Di,et al. Development of a new permeability assay using low-efflux MDCKII cells. , 2011, Journal of pharmaceutical sciences.
[16] Michael Gertz,et al. Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction , 2011, Drug Metabolism and Disposition.
[17] Micaela B. Reddy,et al. Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible , 2011, Biopharmaceutics & drug disposition.
[18] M. Miura,et al. Involvement of Carboxylesterase 1 and 2 in the Hydrolysis of Mycophenolate Mofetil , 2010, Drug Metabolism and Disposition.
[19] Y. Mizuki,et al. Prediction of the Intestinal First-Pass Metabolism of CYP3A Substrates in Humans Using Cynomolgus Monkeys , 2010, Drug Metabolism and Disposition.
[20] Kayoko Ohura,et al. The role of intestinal carboxylesterase in the oral absorption of prodrugs. , 2010, Current drug metabolism.
[21] Michael Gertz,et al. Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data , 2010, Drug Metabolism and Disposition.
[22] John D. Davis,et al. Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. , 2008, Current drug metabolism.
[23] A. Galetin,et al. Potential role of intestinal first-pass metabolism in the prediction of drug–drug interactions , 2008, Expert opinion on drug metabolism & toxicology.
[24] Masakiyo Hosokawa,et al. Structure and Catalytic Properties of Carboxylesterase Isozymes Involved in Metabolic Activation of Prodrugs , 2008, Molecules.
[25] T. Kamataki,et al. Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: is CYP2C76 the only monkey-specific CYP gene responsible for species differences in drug metabolism? , 2007, Archives of biochemistry and biophysics.
[26] Masoud Jamei,et al. Prediction of intestinal first-pass drug metabolism. , 2007, Current drug metabolism.
[27] Teruko Imai,et al. Carboxylesterase in the liver and small intestine of experimental animals and human. , 2007, Life sciences.
[28] A. Dokoumetzidis,et al. Predictive models for oral drug absorption: from in silico methods to integrated dynamical models , 2007, Expert opinion on drug metabolism & toxicology.
[29] Teruko Imai,et al. Substrate Specificity of Carboxylesterase Isozymes and Their Contribution to Hydrolase Activity in Human Liver and Small Intestine , 2006, Drug Metabolism and Disposition.
[30] T. Imai,et al. IDENTIFICATION OF ESTERASES EXPRESSED IN CACO-2 CELLS AND EFFECTS OF THEIR HYDROLYZING ACTIVITY IN PREDICTING HUMAN INTESTINAL ABSORPTION , 2005, Drug Metabolism and Disposition.
[31] B. Vig,et al. Targeted delivery to PEPT1-overexpressing cells: Acidic, basic, and secondary floxuridine amino acid ester prodrugs , 2005, Molecular Cancer Therapeutics.
[32] A. Avdeef,et al. PAMPA--a drug absorption in vitro model 13. Chemical selectivity due to membrane hydrogen bonding: in combo comparisons of HDM-, DOPC-, and DS-PAMPA models. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[33] K. Beaumont,et al. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. , 2003, Current drug metabolism.
[34] Y. Rojanasakul,et al. Characterization of Mefenamic Acid-Guaiacol Ester: Stability and Transport Across Caco-2 Cell Monolayers , 2002, Pharmaceutical Research.
[35] Younggil Kwon,et al. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists , 2001, Springer US.
[36] B Agoram,et al. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.
[37] J. DeSesso,et al. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[38] Y Zhang,et al. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. , 1999, Journal of controlled release : official journal of the Controlled Release Society.
[39] Lawrence X. Yu,et al. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans , 1996 .
[40] Hans Lennernäs,et al. EXPERIMENTAL ESTIMATION OF THE EFFECTIVE UNSTIRRED WATER LAYER THICKNESS IN THE HUMAN JEJUNUM, AND ITS IMPORTANCE IN ORAL-DRUG ABSORPTION , 1995 .
[41] T. Kamataki,et al. Molecular cloning of monkey liver cytochrome P-450 cDNAs: similarity of the primary sequences to human cytochromes P-450. , 1992, Biochimica et biophysica acta.
[42] P. Artursson,et al. A method for the determination of cellular permeability coefficients and aqueous boundary layer thickness in monolayers of intestinal epithelial caco 2 cells grown in permeable filter chambers , 1991 .
[43] C. Wilke,et al. Correlation of diffusion coefficients in dilute solutions , 1955 .
[44] K. Tetsuka,et al. Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. , 2012, Drug metabolism and pharmacokinetics.
[45] S. Komuro,et al. Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data. , 2011, Drug metabolism and pharmacokinetics.
[46] Z. Yao,et al. A portal vein cannulation technique for drug discovery in mice , 2008, Lab Animal.
[47] R. Buschmann. Morphometry of the small intestinal enterocytes of the fasted rat and the effects of colchicine , 2004, Cell and Tissue Research.
[48] H. Yamazaki,et al. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans , 1997, Archives of Toxicology.